West Michigan Advisors LLC Buys 509 Shares of Johnson & Johnson (NYSE:JNJ)

West Michigan Advisors LLC grew its stake in Johnson & Johnson (NYSE:JNJ) by 12.9% in the 4th quarter, Holdings Channel reports. The firm owned 4,458 shares of the company’s stock after purchasing an additional 509 shares during the period. West Michigan Advisors LLC’s holdings in Johnson & Johnson were worth $645,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of JNJ. Wealth Group Ltd. bought a new position in shares of Johnson & Johnson in the 3rd quarter worth about $213,000. Swedbank AB grew its position in Johnson & Johnson by 5.3% during the 3rd quarter. Swedbank AB now owns 2,215,108 shares of the company’s stock valued at $358,980,000 after purchasing an additional 111,570 shares during the last quarter. Clear Creek Financial Management LLC grew its position in Johnson & Johnson by 20.1% during the 3rd quarter. Clear Creek Financial Management LLC now owns 6,106 shares of the company’s stock valued at $990,000 after purchasing an additional 1,024 shares during the last quarter. Optas LLC grew its position in Johnson & Johnson by 11.4% during the 3rd quarter. Optas LLC now owns 5,779 shares of the company’s stock valued at $937,000 after purchasing an additional 592 shares during the last quarter. Finally, Private Wealth Partners LLC grew its position in Johnson & Johnson by 5.6% during the 3rd quarter. Private Wealth Partners LLC now owns 80,427 shares of the company’s stock valued at $13,034,000 after purchasing an additional 4,234 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently commented on JNJ shares. Guggenheim increased their price objective on shares of Johnson & Johnson from $162.00 to $166.00 and gave the company a “neutral” rating in a research report on Monday, February 3rd. Barclays increased their price objective on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research report on Tuesday, January 28th. Leerink Partners dropped their price target on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a report on Thursday, January 23rd. Citigroup dropped their price target on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $181.00 price target on shares of Johnson & Johnson in a report on Wednesday, February 19th. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus price target of $170.67.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $167.08 on Tuesday. The firm’s 50 day moving average price is $151.33 and its 200-day moving average price is $156.08. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $402.26 billion, a PE ratio of 25.12, a price-to-earnings-growth ratio of 2.56 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. During the same quarter last year, the business earned $2.29 EPS. The firm’s revenue was up 5.3% compared to the same quarter last year. Equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 2.97%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s payout ratio is 74.59%.

Insiders Place Their Bets

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the firm’s stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares in the company, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Timothy Schmid sold 403 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.